Compounds containing oxazolidinone, triazole and macrolide groups in the treatment of mycobacterial infections

Abstract

Nowadays fixed-dose combinations and me-too drugs are important strategies in the fight against multi-drug resistant microorganisms and other kind of diseases and have been studied by several pharmaceutical companies. Considering this fact the present application from RIB-X Pharmaceuticals (WO2007133803) discloses a series of compounds based on oxazolidinone nucleus with or without triazole and macrolide groups to treat myco bacterial infections, in particular infections caused by multi-drug resistant microorganisms, such as Mycobacterium tuberculosis, and nontuberculosis mycobacteria, such as Mycobacterium avium complex–a combination of bacteria belonging to the genus Mycobacterium.

Keywords::

• macrolides
• Mycobacterium tuberculosis
• oxazolidinones
• triazoles